Moxaverine API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Moxaverine is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Moxaverine or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Moxaverine API 10539-19-2?

Description:
Here you will find a list of producers, manufacturers and distributors of Moxaverine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Moxaverine 
Synonyms:
 
Cas Number:
10539-19-2 
DrugBank number:
DB12251 
Unique Ingredient Identifier:
P3P08Y1XJ4

General Description:

Moxaverine, identified by CAS number 10539-19-2, is a notable compound with significant therapeutic applications. Moxaverine has been investigated for the treatment of Retina, Ocular Physiology, and Regional Blood Flow.

Classification:

Moxaverine belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached, classified under the direct parent group Benzylisoquinolines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Isoquinolines and derivatives class, specifically within the Benzylisoquinolines subclass.

Categories:

Moxaverine is categorized under the following therapeutic classes: Alimentary Tract and Metabolism, Alkaloids, Autonomic Agents, Benzylisoquinolines, Drugs for Functional Gastrointestinal Disorders, Heterocyclic Compounds, Fused-Ring, Isoquinolines, Opiate Alkaloids, Papaverine and Derivatives, Parasympatholytics, Peripheral Nervous System Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Moxaverine is a type of Gastrointestinal Agents


Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).

One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.

Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.

Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.

Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.

In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.